Back

Prevalence and risk of DOACs inappropriate dosing in atrial fibrillation. An analysis of the Swiss-AF and BEAT-AF registries

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Drug treatment for atrial fibrillation Oral Anticoagulation ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Giulia Montrasio

Kantonsspital Aarau, Aarau (Switzerland)

9 More presentations in this session

Presentation thumbnail
Heparin and low-molecular-weight heparin switch associated with an increase in bleeding complications in patients on apixaban undergoing catheter ablation: The AMPER ABLATION study
Doctor W. Amara (Le Raincy-Montfermeil, FR)
Abstract
Presentation thumbnail
Amiodarone treatment duration and reasons for permanent drug discontinuation in patients with atrial fibrillation
Doctor M. Mihajlovic (Belgrade, RS)
Abstract Slides
Presentation thumbnail
Use of direct thrombin inhibitor on the day of atrial fibrillation ablation decreases incidence of silent cerebral ischemia detected by magnetic resonance imaging
Associate Professor M. Harada (Toyoake, JP)
Abstract
Presentation thumbnail
Comparison of efficacy of different anticoagulation strategies used during pulmonary vein isolation in left atrial blood samples
Doctor O. Hajas (Debrecen, HU)
Abstract Slides
Presentation thumbnail
Efficacy and safety of dronedarone after recent cardioversion in patients with atrial fibrillation/flutter: a post-hoc analysis of the EURIDIS/ADONIS trials
Professor H. Crijns (Maastricht, NL)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Drug treatment for atrial fibrillation

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on stroke prevention in atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources